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Atrial fibrillation (AF), as a sustained
arrhythmia, is featured by uncoordinated
atrial activation with the consequent dete-
rioration of mechanical function in the
atrium (Mestroni, 2003; Fye, 2006; Fatkin
et al., 2007; Otway et al., 2007). A
large amount of risk factors for AF have
been identified including ageing, male
sex, hypertension, ischemic heart disease,
myocardial infarction, valvular diseases,
and obesity (Benjamin et al., 1994; Krahn
et al., 1995; Go et al., 2001). AF can cause
several serious complications including
congestive heart failure and stroke (Wolf
et al., 1991; Benjamin et al., 1998; Kannel
et al., 1998; Mestroni, 2003; Piccini et al.,
2012). As amost prevalent type of arrhyth-
mia, AF has a life-time risk of 1 in 4 for
those people aged over 40 in the United
States and Europe (Lloyd-Jones et al.,
2004; Donahue et al., 2005; Benjamin
et al., 2009; Kim et al., 2011). Almost three
million people in the United States are
affected by AF, and the number is esti-
mated to be doubled by year 2050 (Roberts
and Gollob, 2010). In China, at least 10
million AF patients exist (Zhou and Hu,
2008). Similar trends can also be observed
in most other developed and developing
countries worldwide (Tsai et al., 2008).
AF has become a growing global problem.
Dissecting the mechanisms and develop-
ing novel effective therapies for AF are
highly desirable.
Three classical models have been pro-
posed for the genesis of AF, includ-
ing focal activity, single-circuit reentry,
andmultiple-circuit reentrymodel (Fatkin
et al., 2007). The focal-activity hypothesis
points out that AF is started and further
driven by the rapid firing of single or
multiple ectopic foci (Nattel, 2002; Xiao
et al., 2011). The multiple-circuit reentry
hypothesis assumes that several reentry
circuits exist and randomly propagating
wave fronts persist in receptive tissue
while the single-circuit reentry hypothesis
focuses on the interaction of a rotor with
irregular waves in the atrium and “fib-
rillatory conduction,” the spatially vari-
able refractory properties of atrial tissue
(Nattel, 2002; Xiao et al., 2011).
Although AF is a most prevalent type
of arrhythmia, its genetic etiology remains
unclear (Franco et al., 2011). At the very
early beginning, AF is generally appre-
ciated to be uninheritable (Xiao et al.,
2011). Subsequently, 5% of AF patients
and up to 15% of individuals with lone
AF have been identified to have a famil-
ial history (Christophersen et al., 2013),
which encourage the starting of genetic
studies in familial form of AF. Besides that,
the common variants in AF in the general
population have been paid special atten-
tion with the recently published results
from several large genome-wide associa-
tion studies (GWAS) (Darbar et al., 2003;
Fox et al., 2004; Christophersen et al.,
2009; Sinner et al., 2011; Mahida, 2014).
A susceptibility locus for AF on chromo-
some 4q25, which was reported in 2007 in
the first GWAS for AF (Gudbjartsson et al.,
2007) and has been independently repli-
cated in multiple other association studies
(Kaab et al., 2009; Sinner et al., 2011), is
of highly interest. The identified signal at
the 4q25 locus lies within an intergenic
region without any currently known genes
(Sinner et al., 2011; Mahida, 2014) and the
closest gene, paired-like homeodomain 2
(Pitx2), is considered as a most promis-
ing candidate. Pitx2 is located 150,000
bases away and has been reported to con-
tribute to cardiac development (Franco
et al., 2011; Liu et al., 2012).
The Pitx2 gene mainly encodes three
distinct isoforms including Pitx2a, Pitx2b,
and Pitx2c (Schweickert et al., 2000; Cox
et al., 2002). A fourth isoform, Pitx2d
is also expressed in human, function-
ing as a dominant negative protein (Cox
et al., 2002). Pitx2 has been reported to
participate to the establishment of left–
right asymmetry of the heart (Lin et al.,
1999). In addition, Pitx2 plays a criti-
cal role in the development of the left
atrium (Campione et al., 2001, 2002;
Mommersteeg et al., 2007) and pulmonary
vein myocardium as well (Mommersteeg
et al., 2007). Interestingly, pulmonary vein
is a source of AF (Nattel, 2002). Thus, inac-
tivated Pitx2 may affect the development
of pulmonary vein myocardium, con-
tributing to ectopic electric activity from
pulmonary vein. The loss-of-function of
Pitx2 causes several severe cardiovascu-
lar defects, including atrial isomerism,
double inlet left ventricle, abnormal aor-
tic arch remodeling and transposition of
the great arteries (Franco and Campione,
2003; Wang et al., 2013). Since the pub-
lished of the identification of Pitx2 as a
candidate in the first GWAS study, spe-
cial attention has been paid to its poten-
tial role in AF. Knockout of Pitx2 in mice
leads to pro-arrhythmogenic alterations in
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the action potential (Wang et al., 2010;
Chinchilla et al., 2011; Kirchhof et al.,
2011). The expression level of Pitx2c, a
major form of Pitx2 in the adult heart,
has been reported to be impaired in
patients with AF (Chinchilla et al., 2011).
Decreased Pitx2 leads to atrial electri-
cal and structural remodeling (Chinchilla
et al., 2011), both are arrhythmogenic
alterations, and can finally increase suscep-
tibility to atrial arrhythmias (Wang et al.,
2010; Chinchilla et al., 2011; Kirchhof
et al., 2011). Evidences show that the
presence of common single nucleotide
polymorphism (rs2200733, rs1033464) at
the 4q25 locus (near Pitx2) is an inde-
pendent predictor of AF recurrence after
direct current cardioversion (Parvez et al.,
2013). Moreover, rs1033464 has also been
reported as an independent predictor of
successful rhythm control in antiarrhyth-
mic drugs (Parvez et al., 2012). Although
the putative function of Pitx2 in the fetal
and adult heart is largely unknown, accu-
mulating evidences show that defects in
Pitx2 result in defects of cardiac conduc-
tion system (Franco et al., 2011), which
might be a cause of spreading irregu-
lar waves and leads to AF. Promisingly,
Pitx2 has been reported to prevent sus-
ceptibility to atrial arrhythmias through
inhibition of left-sided pacemaker, such
as the SAN-specific genetic program in
left atrium (Wang et al., 2010), provid-
ing a novel therapeutic target for AF. A
Pitx2 conditional knockout mouse which
deletes Pitx2 in postnatal atrium but leav-
ing the developmental function of Pitx2
intact exhibit the phenotype of irregu-
lar R-R interval with disappeared P-wave
amplitude, indicating impaired atrial con-
duction (Tao et al., 2014). Thus, inacti-
vated Pitx2 may also disrupt normal atrial
conduction and thereafter promote re-
rentrant circuits. Accumulating evidence
has indicated that Pitx2 is a promising
therapeutic target for AF. Further under-
standing of the role of Pitx2 in the genesis
of AF holds the potential to be eventually
developed as a novel effective therapy for
this common arrhythmia.
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